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Abstract
Prostate specific membrane antigen (PSMA) is overexpressed in prostatic adenocarcinoma (CaP), and its expression is
negatively regulated by androgen stimulation. However, it is still unclear which factors are involved in this downregulation.
TMPRSS2-ERG fusion is the most common known gene rearrangement in prostate carcinoma. Androgen stimulation can
increase expression of the TMPRSS2-ERG fusion in fusion positive prostate cancer cells. The purpose of this investigation is to
determine whether PSMA expression can be regulated by the TMPRSS2-ERG gene fusion. We employed two PSMA positive
cell lines: VCaP cells, which harbor TMPRSS2-ERG fusion, and LNCaP cells, which lack the fusion. After 24 hours of androgen
treatment, TMPRSS2-ERG mRNA level was increased in VCaP cells. PSMA mRNA level was dramatically decreased in VCaP
cells, while it only has moderate change in LNCaP cells. Treatment with the androgen antagonist flutamide partially restored
PSMA expression in androgen-treated VCaP cells. Knocking down ERG by siRNA in VCaP cells enhances PSMA expression
both in the presence and absence of synthetic androgen R1881. Overexpressing TMPRSS2-ERG fusions in LNCaP cells
downregulated PSMA both in the presence or absence of R1881, while overexpressing wild type ERG did not. Using PSMA-
based luciferase reporter assays, we found TMPRSS2-ERG fusion can inhibit PSMA activity at the transcriptional level. Our
data indicated that downregulation of PSMA in androgen-treated VCaP cells appears partially mediated by TMPRSS2-ERG
gene fusion.
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Introduction
Prostate specific membrane antigen (PSMA) is a type II
transmembrane glycoprotein overexpressed in prostate carcinoma.
The protein consists of 750 amino acids with a molecular weight
,100 kDa [1]. The extracellular domain has activities as a folate
hydrolase (cleaving the terminal glutamates from c-linked poly-
glutamates) and NAALADase (cleaving the terminal glutamate
from a-linked N-acetylaspartyl glutamate). PSMA can undergo
internalization, and its intracellular domain is known to bind to
actin binding protein filamin A [2,3]. Nearly all prostate cancer
cells express PSMA, and its expression has been correlated with
aggressive disease [4,5,6]. In addition to normal prostate gland,
benign prostatic hyperplasia (BPH), and prostate cancer (PCa),
PSMA is also expressed in the neovasculature of multiple solid
tumors [7,8,9,10]. Higher PSMA expression is also found in
cancer cells from castration-resistant prostate cancer patients.
Increased PSMA expression is reported to correlate with the risk of
early prostate cancer recurrence after radical prostatectomy
[5,11,12]. Investigating the mechanism of PSMA regulation will
allow us to better understand the mechanisms and functions of
PSMA in prostate cancer.
A common genetic alteration in prostate cancer is a signature
gene fusion between the androgen-regulated TMPRSS2 and the
transformation-specific (ETS) transcription factor family members
[13,14,15,16]. Of those, the TMPRSS2-ERG fusion is the most
common known gene rearrangement in prostate cancer. Studies
found that approximately 50% of prostate cancers harbor
TMPRSS2-ERG fusions, of which greater than 90% over-express
ERG [17]. TMPRSS2-ERG fusions alter prostate cancer progres-
sion by promoting cell invasion, activating C-MYC oncogene and
abrogating prostate epithelial differentiation [15,18,19]. Recent
publications have reported that prostate cancer containing
TMPRSS2-ERG fusions are significantly enriched for loss of the
tumor suppressor PTEN [20]. TMPRSS2-ERG cooperates with loss
of PTEN to further promote prostate cancer progression [20,21].
However, it has been controversial as to whether this fusion product
results in increased aggressive behavior in the prostate. While a
significant amount of investigations have been done on the tumor
biological functions of TMPRSS2 fusion-driven ETS overexpres-
sion in prostate cancer, few papers have reported on its potential
downstream targets.
While PSMA is upregulated overall in prostate cancer, it is
strongly overexpressed in 50% of prostate cancer specimens
[5,6,22]. Although TMPRSS2-ERG is also found in 50% of
prostate cancer specimens [14,15,17], it is unknown if, or to what
extent these populations overlap. PSMA is upregulated by
androgen ablation, and androgens can stimulate TMPRSS2-ERG
gene fusion, as the TMPRSS2 promoter has an androgen-
responsive element. This information provides a potential link
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fusion-positive prostate cancer cells. We hypothesized that PSMA
expression could be regulated by the TMPRSS2-ERG fusion.
VCaP cells express the TMPRSS2-ERG fusion, while LNCaP cells
do not. Therefore, we investigated PSMA regulation in
TMPRSS2-ERG fusion-positive VCaP and fusion-negative
LNCaP prostate cancer cells. Our data suggest that downregula-
tion of PSMA by androgen is mediated by TMPRSS2-ERG gene
fusion in VCaP cells.
Materials and Methods
Cell culture and transfection
Lymph node metastasis-derived LNCaP cells (ATCC) were
grown in RPMI 1640 medium (Mediatech), and bone metastasis-
derived VCaP cells (ATCC) were grown in modified DMEM
medium (Cat# 30-2002, ATCC), both with 10% fetal bovine
serum (USB Corp) in a humidified atmosphere of 5% CO2 at
37uC. At 60–80% confluence cell lines were incubated with
vehicle DMSO or 10 mM flutamide (androgen receptor antago-
nist; Sigma) for 2 hours before treatment with 5 nM of R1881
(synthetic androgen, Perkin Elmer) for 24 hours. TMPRSS2-ERG
fusion transcript isoforms (III, III+72, VI, VI+72) [18] or ERG
cDNA (RC218892, OriGene Technologies, Inc.) were transfected
into LNCaP cells by Lipofectamine 2000 (Cat# 11668-019,
Invitrogen). The empty vectors were pcDNA3.1 and pCMV6-
Entry respectively. Transfections were performed according to the
manufacturer’s instruction (Invitrogen). The ratio of DNA (mg) to
Lipofectamine 2000 (ml) is 1:2.5. Expression of ERG fusion
proteins and wild type ERG were checked by western blot.
ERG knockdown with small interfering RNA (siRNA)
For siRNA knockdown of ERG, siRNA against human ERG
(NM_004440) was designed as 59-GACATCCTTCTCTCACAT-
39 (Ambion, Austin, TX) or purchased from Dharmacon (D-
001210-01; Lafayette, CO). They are designated as siERG-1 (from
Ambion) and siERG-2 (from Dharmacon) respectively. Negative
control #1 siRNA (non-targeting) (Cat#4390843; Ambion) or
siRNA against ERG was transfected into VCaP cells as indicated,
using Oligofectamine (Cat# 12252-011, Invitrogen). Transfec-
tions were performed according to the manufacturer’s instruction
(Invitrogen). VCaP cells were seeded into 12-well plate one day
before transfection. 200 nM of siRNA and 3 ml of Oligofectamine
were used for each transfection. After 24 hours, a second identical
transfection was carried out and cells were harvested 24 hours
later. siRNA knockdown of ERG was tested by both quantitative
polymerase chain reaction (qPCR) and immunoblot analysis.
Experiments were done in triplicate.
Detection of proteins by Western Blot analysis
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1% Igepal CA-630, 0.5% Na Deoxycholate, 0.1%
SDS, 1 mM EDTA, 50 mM NaF, 200 mM Na Orthovanadate)
supplemented with protease inhibitor cocktail (Cat# 11836-
153001, Roche). Protein samples were run in 7.5% Tris-HCL
precast ready gel (Cat# 161-1154, BIO-RAD) and transferred
into PVDF membrane. Blots were blocked in 5% skim milk and
incubated with anti-ERG antibody (1: 1000 dilution) (Cat# sc-
354, Santa Cruz Biotechnology), anti-PSMA antibody GCP-04
(1:10000 dilution) (gift from Dr. Jan Konvalinka, Academy of
Sciences of the Czech Republic, Prague, Czech Republic), anti-V5
antibody (1: 1000 dilution) (Cat# R961-25, Invitrogen), or
anti-GAPDH (1: 20000 dilution) (Cat# 2-RGM2, Advanced
ImmunoChemical Inc.). HRP labeled goat anti-rabbit or goat
anti-mouse was used as secondary antibody (1:5000; Pierce).
Signal was detected by chemiluminescent substrate from Pierce
(Cat# 34080).
Real-Time RT-PCR analysis
Gene expression was verified by real-time reverse transcription
(RT)-PCR. RNA was isolated using RNA-Bee (Cat# CS-105B,
TEL-TEST, INC.) and purified by RNeasy mini kit (Cat# 74104,
QIAGEN). The first strand of cDNA was synthesized from RNA
samples with an iScript cDNA synthesis kit (Cat# 170-8890, Bio-
Rad Laboratories). 500 ng of total RNA from each sample was
applied to each reaction. 20 mL of complete reaction mix was
incubated at 25 uC for 5 min, followed by 42 uC for 30 min and
85 uC for 5 min. After cDNA synthesis, 2 mL of reaction was then
used to set up PCR reactions with an iQ SYBR Green Supermix
kit (Cat# 170-8882, Bio-Rad). Total reaction volume for PCR was
set to 20 mL in 2x SYBR Green Supermix with gene specific
primers. Reactions were run at 95 uC for 10 sec, 60 uC for 30 sec
followed by 40 cycles. Fluorescent data were collected in an
iCycler iQ detection system (Bio-Rad). For each sample in a given
experiment, duplicate reactions were set up with a primer pair for
the gene of interest, as well as duplicate reactions with a primer
pair for phosphogluconate dehydrogenase (PGD), which was used
as an endogenous reference. Using the comparative threshold
cycles (CT) method, the quantification normalized to PGD and
relative to untreated, parental cells was performed. Fold changes
were calculated using the formula 2
2DDCT, where DCt is
Ct(target gene)-Ct(PGD), DDCt is DCt(treatment)- DCt(control). Experi-
ments were done in triplicate. Primer sets: PSMA forward: 59-
TCTGCTCGCGCCGAGATGTG-39; PSMA reverse: 59-ATTT-
TATAAACCACCCGAAG-39; TMPRSS2/ERG forward: 59-
TAGGCGCGAGCTAAGCAGGAG-39; TMPRSS2/ERG re-
verse: 59-ACGCGGTCATCTGTGTCTTA-39; PGD forward:
59-AGACCATCTTCCAAGGCATTG-39; PGD reverse: 59-
GTGGTATGCCTCACAGATCAG-39.
Luciferase reporter assay
VCaP cells were transfected with plasmid for PSM-Luc
(contains PSMA promoter and enhancer) and Renilla-Luc
luciferase reporter genes. Twenty-four hours post-transfection,
cells were cultured in DMEM medium containing 9% charcoal-
stripped fetal bovine serum (C-FBS, Hyclone) +1% normal FBS,
and cultured for another 24 hours in the presence or absence of
R1881, flutamide, or bicalutamide. Prior to harvest, LNCaP cells
were co-transfected with TMPRSS2-ERG fusion transcript
isoforms and PSM-Luc and Renilla-Luc. Twenty-four hours
post-transfection, cells were cultured in phenol red-free RPMI
1640 (Invitrogen) containing 9% charcoal-stripped serum (CSS)
+1% normal serum, and cultured for another 24 hours in the
presence or absence of R1881. Cells were harvested, and firefly
and Renilla luciferase activities were measured using the Dual-
Luciferase Reporter Assay System according to the manufacturer’s
instruction (Promega).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed by
using a ChIP kit according to the manufacturer’s instructions
(ab500, Abcam Inc.). In brief, about 3610
6 VCaP cells were fixed
in 37% formaldehyde before lysis. Chromsomal DNA was sheared
by using a sonicator to an optimal DNA fragment size of 200–
1000 bp. Anti-ERG (sc-354, Santa Cruz) antibody was used in the
immunoprecipitation to pull down ERG protein and DNA
complex. Rabbit IgG was used as negative control. After DNA
purification, 0.5 ul each of input DNA, ERG-enriched, or rabbit
PSMA Regulation by TMPRSS2-ERG Gene Fusion
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fragment of PSMA promoter was amplified by the upstream 59-
TGCACGGCCTCTCTCACGGA-39 and downstream 59-
GGCTATGTCTGGCTACTGTCTTA-39 primers.
Statistical analysis
For real-time PCR, the DCt values of treatment groups and
vehicle control were compared using 2-sided paired t-tests which
blocked on experimental replicates. For the luciferase assay, we
analyzed data by using two sample t-test due to the pooled nature
of the experiment. Significance was accepted when p,0.05.
Results
Inhibition of PSMA expression by the nonaromatizable
androgen R1881 in VCaP cells
Both VCaP and LNCaP cells were treated with vehicle or the
androgen antagonist flutamide prior to treatment with the
synthetic androgen R1881. After 24 hours treatment,
TMPRSS2-ERG mRNA and protein levels were induced in
VCaP cells by R1881, and the increased expression was
attenuated by the addition of flutamide (Fig. 1A). PSMA mRNA
levels dramatically decreased in VCaP cells after R1881 exposure
for 24 hours, and treatment with flutamide partially restored
PSMA mRNA level (Fig. 1B). After R1881 treatment for 3 days,
PSMA protein levels were also decreased in VCaP cells (Fig. 1C).
Since PSMA protein has a long half life of 55 hours [23], it took a
longer time to decrease its protein level than to decrease mRNA
level by R1881. Reports have shown PSMA is up-regulated by
androgen ablation [12]; however, we found that the response of
PSMA to androgen treatment was different in VCaP and LNCaP
prostate cancer cell lines. R1881 significantly reduces PSMA in
VCaP cells while it has a modest decrease in LNCaP cells.
Interestingly, we found AR mRNA levels in response to its ligand
were also different in these two cell lines. AR mRNA is
dramatically reduced by R1881 in VCaP cells, while it has
minimal change in LNCaP cells (data not shown). Our result is
consistent with Makkonen’s findings published recently [24].
VCaP cells harbor the TMPRSS2-ERG fusion and contain wild
type AR, while LNCaP cells lack this fusion gene and have a
mutated AR. Therefore, it is possible that the differential
inhibition of PSMA by androgen treatment in VCaP cells and
LNCaP cells is due to either the TMPRSS2-ERG fusion or the
different type of AR. Moreover, AR expression level is higher in
VCaP cells than in LNCaP cells, and the pattern for regulation of
AR target gene expression by amplification of AR is also different
Figure 1. Inhibition of PSMA by androgen in VCaP cells. A, Expression levels of TMPRSS2-ERG in VCaP cells by real-time PCR, normalized to
PGD mRNA level. ERG protein level was measured by western blot after treatment with 5 nM of R1881 or 10 mM of antagonist flutamide for 1 day. B,
PSMA expression was detected by real-time PCR in VCaP cells, normalized to PGD. (Cells were treated the same as in Fig 1A). C, PSMA protein levels
were checked by western blot in VCaP cells treated with 5 nM of R1881 for 0–5 days. For real-time PCR, cells were treated with vehicle or androgen
antagonist flutamide for 2 hours prior to the treatment of the synthetic androgen R1881 for 24 hours. Experiments were done in triplicate.
doi:10.1371/journal.pone.0021319.g001
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determined PSMA expression following siRNA knock down of
ERG in VCaP cells.
ERG knockdown enhances PSMA expression in VCaP cells
It is reported that the TMPRSS2-ERG fusion transcripts
encode truncated ERG proteins at the amino terminus [19] and
the vast majority of total ERG mRNA represents fusion gene
transcripts. Therefore, by knocking down ERG, we can effectively
evaluate the function of the TMPRSS2-ERG fusions. VCaP cells
were transfected with siRNA for 3 days. Knocking down ERG was
verified by real-time PCR. ERG mRNA level was reduced by 50%
using specific ERG siRNA (Fig. 2A). Further knocking down of
ERG was achieved by using combination of two siRNA siERG-1
and siERG-2 (Fig. 2A). So this siRNA combination was used in the
following experiment. Partial silencing of ERG alone can enhance
PSMA expression in VCaP cells (Fig. 2B, 2C). In addition, R1881-
induced downregulation of PSMA expression was partially
attenuated in ERG knockdown VCaP cells (Fig. 2B). These data
indicate that either or both of the TMPRSS2-ERG fusion or wild
type ERG can suppress PSMA expression in VCaP cells. To verify
what type of ERG was involved in PSMA expression, next we
checked their effects by overexpressing TMPRSS2-ERG fusion or
wild type ERG in LNCaP cells.
Overexpression of TMPRSS2-ERG fusions decreased
PSMA expression in LNCaP cells
TMPRSS2-ERG fusion isoforms have variable biological
activities [18]. Of the fusion isoforms, the most common
transcripts are type III (TMPRSS2 exon 1 fused to ERG exon
4) and type VI (TMPRSS2 exon 2 fused with ERG exon 4). Type
III encodes a truncated ERG protein, while type VI encodes a true
fusion protein [18]. Recently a 72-bp exon was found in some
alternatively spliced fusion isoforms. The presence of the 72 bp
exon has a significant biological function in cell proliferation [18].
Both of the type III+72 and type VI+72 isoforms can enhance cell
proliferation. To further identify whether inhibition of PSMA is
mediated by wild type ERG or by different TMPRSS2-ERG
fusions, we transfected these ERG fusion constructs into LNCaP
cells, which is ERG fusion-negative. The dosage of Lipofectamine
2000 used for transfection has minimal cytotoxicity on cell growth
(data not shown). PSMA mRNA level had a modest decrease in
LNCaP cells after R1881 exposure for 24 hours (Fig. 3A). When
LNCaP cells were transfected with TMPRSS2-ERG fusion
constructs, ERG fusion proteins were detected by using anti-V5
antibody (Fig. 3B). We found PSMA was downregulated, and its
suppression was enhanced in the presence of R1881 (Fig. 3C). On
the other hand, when LNCaP cells were transfected with normal
ERG (Refseq: NM_004449.3), no change in PSMA expression
was observed in this cell line (Fig. 3D, 3E). When treated with
R1881, which can partially inhibit PSMA expression, the extent of
inhibition was to the same extent both in the presence or absence
of ERG (Fig. 3E). Given that the transfection efficiency in LNCaP
cells is only around 50% by Lipofectamine (data not shown), and
that we only found partial inhibition of PSMA in LNCaP cells by
transient transfection of TMPRSS2-ERG fusions, more complete
inhibition of PSMA expression would likely be achieved with a
higher transfection efficiency. We did not see any different effect
on PSMA inhibition among the different types of alternate
Figure 2. Knocking down ERG by siRNA enhances PSMA expression in VCaP cells. A, Cells were transfected with different ERG siRNA by
oligofectamine for 48 hours. ERG expression levels were tested by quantitative real-time PCR, normalized to PGD mRNA level. B, Real-time PCR for
PSMA expression in ERG knockdown VCaP cells. Cells were treated with or without R1881 for 24 hours after 48 hours treatment of siRNA. C, Western
blot for ERG and PSMA expression in ERG knockdown VCaP cells. Cells were harvested 72 hours post siRNA transfection.
doi:10.1371/journal.pone.0021319.g002
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inhibition of PSMA by androgen in VCaP cells may be mediated
by truncated ERG or fusion proteins that are encoded by
TMPRSS2-ERG, not by normal ERG protein.
Inhibiton of PSMA luciferase activity by TMPRSS2-ERG
According to MAT inspector software (http://www.genomatix.
de/index.html), we found potential ETS transcription binding
sites on the PSMA promoter and enhancer (data not shown). One
of these binding sites on the PSMA promoter (nt 943-963) was
highly conservative, according to computational prediction
(http://genome.ucsc.edu/index.html; http://weblogo.berkeley.
edu/) (Fig. 4A). We hypothesized that TMPRSS2-ERG can
regulate PSMA at the transcription level. Therefore, we performed
a ChIP assay and also transfected a luciferase reporter gene that
contains the PSMA promoter and enhancer sequences into both
VCaP and TMPRSS2-ERG-transfected LNCaP cells or its
derivative cell line, C4-2. Recruitment of ERG to the PSMA
promoter in VCaP cells was detected by ChIP assay (Fig. 4A).
PSMA luciferase activity was inhibited in VCaP cells when treated
with R1881 for 24 hours. Flutamide can reverse this inhibition
(Fig. 4B). LNCaP and C4-2 cells that were cotransfected with
TMPRSS2-ERG fusion isoforms and the PSMA luciferase
reporter gene showed that different TMPRSS2-ERG isoforms
alone can inhibit PSMA transcription activity, and the activity was
further inhibited by R1881 treatment (Fig. 4C and 4D). These
data confirm that TMPRSS2-ERG fusion can inhibit PSMA
expression at the transcription level.
Discussion
Increased PSMA expression has been correlated with a high
Gleason score of disease and with tumor recurrence in prostate
cancer. In this study, we found PSMA was downregulated by
TMPRSS2-ERG fusion in VCaP prostate cancer cells. These are
the first data to identify a mechanism for androgen signaling
pathways involved in PSMA regulation. Recent reports indicated
that the TMPRSS2-ERG fusion gene was present and expressed in
pre-surgery androgen ablation patients [25]. In addition, ERG
was found in circulating tumor cells from patients with castration-
resistant prostate cancer [26]. Androgen ablation inhibits the
expression of TMPRSS2-ERG. Moreover, patients with expression
of the fusion gene had earlier prostate specific antigen (PSA)
recurrence after radical prostatectomy [25]. Our findings
demonstrate that, in VCaP cells, TMPRSS2-ERG fusions, but
not wild type ERG, suppress PSMA expression. As there is an
Figure 3. Overexpression of TMPRSS2-ERG fusions decreased PSMA expression in LNCaP cells. A, PSMA expression was detected by real-
time PCR in LNCaP cells, normalized to PGD mRNA level. Cells were treated with vehicle DMSO or androgen antagonist flutamide for 2 hours prior to
the treatment of the synthetic androgen R1881 for 24 hours. B, TMPRSS2-ERG fusion protein levels were checked by Western blot using anti-V5
antibody. LNCaP cells were transfected with fusion type III, III+72, VI, VI+72, or empty vector for 48 hours. C, Real-time PCR detected PSMA mRNA
level in TMPRSS2-ERG fusion-transfected LNCaP cells. Cells were transfected with fusions or empty vector for 48 hours, then treated with or without
R1881 for 24 hours. D, ERG expression level in ERG-transfected LNCaP cells by western blot. Cells were transfected with full length ERG for 48 hours. E,
PSMA mRNA level in ERG overexpressing LNCaP cell. Cells were treated with or without R1881 for 24 hours post 48 hours of transfection. Experiments
were done in triplicate.
doi:10.1371/journal.pone.0021319.g003
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it seems unlikely that studies claiming high expression of PSMA
correlates to higher percentage and earlier failure of PSA would
also be occurring in those the TMPRSS-ERG protein is expressed.
Developing results from ongoing studies of prostate tissue
microarrays demonstrated a negative correlation between PSMA
expression and ERG expression in Gleason Score 7 prostate
cancer (communication with Dr. Magi-Galluzzi Cristina from
Cleveland Clinic), which is consistent with our in vitro findings.
Androgen signaling is important for prostate cancer growth and
survival. Androgen exerts its biological functions through binding
to the AR [27]. Overexpression of AR was found in castration-
resistant prostate cancer [28,29]. Investigators reported that high
levels of AR in androgen deprivation therapy downregulated
TMPRSS2-ERG fusion. The fusion gene can be up-regulated at a
late time by reactivating AR in castration-resistant prostate cancer
[30]. Also, ERG can disrupt AR signaling by inhibiting AR
expression [31]. In our study, we found that PSMA could be a
potential downstream target of TMPRSS2-ERG fusion in the AR
signaling pathway. Since there is a correlation between AR and
TMPRSS2-ERG expression, more work needs to be done to
further address the role of AR in ERG fusion mediated PSMA
expression.
We observed that PSMA regulation by androgen could be
mediated by the TMPRSS2-ERG fusion. Knocking down mutant
ERG can increase PSMA expression. This finding suggests that, in
men with prostate cancers bearing the TMPRSS2-ERG fusion, a
short course of androgen ablation might upregulate PSMA and
facilitate therapeutic targeting and/or imaging based on PSMA.
The androgen receptor remains an important target. Androgen
synthesis inhibitors and new more effective antiandrogens are
demonstrating encouraging responses in castrate resistant disease.
Still, resistance to these therapies will eventually develop, and
other non-androgen based therapies such as linked toxin targeting
may add to the arsenal of therapeutic agents available for
treatment. Since PSMA is a promising target for prostate cancer
therapy and imaging, further elucidation of the relationship
between TMPRSS2 gene fusions and PSMA could reveal novel
pathways for enhancing targeted prostate cancer treatment.
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